[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2014204666B2 - Benzylamine derivatives - Google Patents

Benzylamine derivatives Download PDF

Info

Publication number
AU2014204666B2
AU2014204666B2 AU2014204666A AU2014204666A AU2014204666B2 AU 2014204666 B2 AU2014204666 B2 AU 2014204666B2 AU 2014204666 A AU2014204666 A AU 2014204666A AU 2014204666 A AU2014204666 A AU 2014204666A AU 2014204666 B2 AU2014204666 B2 AU 2014204666B2
Authority
AU
Australia
Prior art keywords
ylmethyl
methyl
aminomethyl
carboxylic acid
benzylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014204666A
Other versions
AU2014204666A1 (en
Inventor
Christine Elizabeth Allan
Andrzej Roman Batt
Rebecca Louise DAVIE
Hannah Joy EDWARDS
David Michael Evans
Stephen John PETHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of AU2014204666A1 publication Critical patent/AU2014204666A1/en
Application granted granted Critical
Publication of AU2014204666B2 publication Critical patent/AU2014204666B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

Description

BENZYLAMINE DERIVATIVES
This invention relates to benzylamine derivatives and to pharmaceutical compositions containing and the uses of, such derivatives.
Background to the Invention
The benzylamine derivatives of the present invention are inhibitors of plasma kallikrein and have a number of therapeutic applications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
Plasma kallikrein is a trypsin-like serine protease that can liberate kinins from kininogens (see K. D. Bhoola etal., "Kallikrein-Kinin Cascade", Encyclopedia of Respiratory Medicine, p483-493; J. W. Bryant etal., "Human plasma kallikrein-kinin system: physiological and biochemical parameters" Cardiovascular and haematological agents in medicinal chemistry, 7, p234-250, 2009; K. D. Bhoola etal., Pharmacological Rev., 1992, 44, 1; and D. J. Campbell, "Towards understanding the kallikrein-kinin system: insights from the measurement of kinin peptides", Brazilian Journal of Medical and Biological Research 2000, 33, 665-677). It is an essential member of the intrinsic blood coagulation cascade although its role in this cascade does not involve the release of bradykinin or enzymatic cleavage. Plasma prekallikrein is encoded by a single gene and synthesized in the liver. It is secreted by hepatocytes as an inactive plasma prekallikrein that circulates in plasma as a heterodimer complex bound to high molecular weight kininogen which is activated to give the active plasma kallikrein. Kinins are potent mediators of inflammation that act through G protein-coupled receptors and antagonists of kinins (such as bradykinin antagonists) have previously been investigated as potential therapeutic agents for the treatment of a number of disorders (F. Marceau and D. Regoli, Nature Rev., Drug Discovery, 2004, 3, 845-852).
Plasma kallikrein is thought to play a role in a number of inflammatory disorders. The major inhibitor of plasma kallikrein is the serpin C1 esterase inhibitor. Patients who present with a genetic deficiency in C1 esterase inhibitor suffer from hereditary angioedema (HAE) which results in intermittent swelling of face, hands, throat, gastro-intestinal tract and genitals. Blisters formed during acute episodes contain high levels of plasma kallikrein which cleaves high molecular weight kininogen liberating bradykinin leading to increased vascular permeability. Treatment with a large protein plasma kallikrein inhibitor has been shown to effectively treat HAE by preventing the release of bradykinin which causes increased vascular permeability (A. Lehmann "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery" Expert Opin. Biol. Ther. 8, p1187-99).
The plasma kallikrein-kinin system is abnormally abundant in patients with advanced diabetic macular edema. It has been recently published that plasma kallikrein contributes to retinal vascular dysfunctions in diabetic rats (A. Clermont etal. "Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats" Diabetes, 2011, 60, p159098). Furthermore, administration of the plasma kallikrein inhibitor ASP-440 ameliorated both retinal vascular permeability and retinal blood flow abnormalities in diabetic rats. Therefore a plasma kallikrein inhibitor should have utility as a treatment to reduce retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
Other complications of diabetes such as cerebral haemorrhage, nephropathy, cardiomyopathy and neuropathy, all of which have associations with plasma kallikrein may also be considered as targets for a plasma kallikrein inhibitor.
Synthetic and small molecule plasma kallikrein inhibitors have been described previously, for example by Garrett et al. ("Peptide aldehyde...." J. Peptide Res. 52, p62-71 (1998)), T. Griesbacher et al. ("Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats" British Journal of Pharmacology 137, p692-700 (2002)), Evans ("Selective dipeptide inhibitors of kallikrein" WO03/076458), Szelke etal. ("Kininogenase inhibitors" WO92/04371), D. M. Evans etal. (Immunolpharmacology, 32, p115-116 (1996)), Szelke etal. ("Kininogen inhibitors" WO95/07921), Antonsson etal. ("New peptides derivatives" W094/29335), J. Corte et al. (’’Six membered heterocycles useful as serine protease inhibitors” W02005/123680), J. Sturzbecher etal. (Brazilian J. Med. Biol. Res 27, p1929-34 (1994)), Kettner etal. (US 5,187,157), N. Teno etal. (Chem. Pharm. Bull. 41, p1079-1090 (1993)), W. B. Young etal. ("Small molecule inhibitors of plasma kallikrein" Bioorg. Med. Chem. Letts. 16, p2034-2036 (2006)), Okada etal. ("Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship" Chem. Pharm. Bull. 48, p1964-72 (2000)), Steinmetzer et al. ("Trypsin-like serine protease inhibitors and their preparation and use" WO08/049595), Zhang et al. ("Discovery of highly potent small molecule kallikrein inhibitors" Medicinal Chemistry 2, p545553 (2006)), Sinha etal. ("Inhibitors of plasma kallikrein" W008/016883), Shigenaga et al. (“Plasma Kallikrein Inhibitors” WO2011/118672), and Kolte etal. (“Biochemical characterization of a novel high-affinity and specific kallikrein inhibitor”, British Journal of Pharmacology (2011), 162(7), 1639-1649). Also, Steinmetzer et al. (“Serine protease inhibitors” WO2012/004678) describes cyclized peptide analogs which are inhibitors of human plasmin and plasma kallikrein.
To date, no small molecule synthetic plasma kallikrein inhibitor has been approved for medical use. The molecules described in the known art suffer from limitations such as poor selectivity over related enzymes such as KLK1, thrombin and other serine proteases, and poor oral availability. The large protein plasma kallikrein inhibitors present risks of anaphylactic reactions, as has been reported for Ecallantide. Thus there remains a need for compounds that selectively inhibit plasma kallikrein, that do not induce anaphylaxis and that are orally available. Furthermore, the vast majority of molecules in the known art feature a highly polar and ionisable guanidine or amidine functionality. It is well known that such functionalities may be limiting to gut permeability and therefore to oral availability. For example, it has been reported by Tamie J. Chilcote and Sukanto Sinha (“ASP-634: An Oral Drug Candidate for Diabetic MacularEdema”, ARVO 2012 May 6th - May 9th, 2012, Fort Lauderdale, Florida, Presentation 2240) that ASP-440, a benzamidine, suffers from poor oral availability. It is further reported that absorption may be improved by creating a prodrug such as ASP-634. However, it is well known that prodrugs can suffer from several drawbacks, for example, poor chemical stability and potential toxicity from the inert carrier or from unexpected metabolites.
There are only few reports of plasma kallikrein inhibitors that do not feature guanidine or amidine functionalities. For example, BioCryst Pharmaceuticals Inc. have reported the discovery of BCX4161 which is a benzylamine derivative (http://files.shareholder.com/downloads/BCRX/ 0x0x403076/97a18d6e-1621-4fc6-8f5f-d0828bddab4f/Dr._Yarlagadda_S._Babu_Ph.D._Drug_ Discovery.pdf). Data relating to its oral exposure in the rat are reported in their Second Quarter 2012 Financial Results & Corporate Update. Oral efficacy in a rat model is reported but at the relatively high dose of 100 mg/kg. Another example is Brandi etal. (“N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein” WO2012/017020), which describes compounds that feature an amino-pyridine functionality. Oral efficacy in a rat model is demonstrated at relatively high doses of 30 mg/kg and 100 mg/kg but the pharmacokinetic profile is not reported. Thus it is not yet known whether such compounds will provide sufficient oral availability or efficacy for progression to the clinic.
Therefore there remains a need to develop new plasma kallikrein inhibitors that will have utility to treat a wide range of disorders, in particular to reduce retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. Preferred compounds will possess a good pharmacokinetic profile and in particular will be suitable as drugs for oral delivery.
Summary of the Invention
The present invention relates to a series of benzylamine derivatives that are inhibitors of plasma kallikrein. These compounds demonstrate good selectivity for plasma kallikrein and are potentially useful in the treatment of impaired visual acuity, diabetic retinopathy, macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery. The invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions.
In an aspect, the present invention provides compounds of formula I
Formula (I) wherein, V is selected from C and N such that the aromatic ring containing V is phenyl or pyridine; R2 is absent when V is N; or, when present, R2 is selected from H, alkyl, alkoxy, CN, halo and CF3; R1 and R3 are independently selected from H, alkyl, alkoxy, CN, halo and CF3; W, X, Y and Z are independently selected from C, N, O and S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; wherein, R5, R6 and R7 are independently absent or independently selected from H, alkyl, halo, aryl, heteroaryl and CF3; P is -C(R10)(R11)NH2; R8 and R9 are independently selected from H and alkyl, or may together form a cycloalkyl ring; R10 and R11 are independently selected from H and alkyl, or may together form a cycloalkyl ring or a cyclic ether; A is selected from N-linked morpholine, aryl, heteroaryl, alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (CrC6)alkoxy, OH, CN, CF3, -COOR12, -CONR12R13, H(CH2)1-3CON(R12)( CH2)i.3-, fluoro and -NR12R13; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms; wherein cycloalkyl may be optionally substituted with a substituent selected from alkyl, alkoxy and NR12R13; a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom; alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (CrC6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from aryl, OH, CN, CF3, -COOR12, -CONR12R13, fluoro and NR12R13; aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i.3-arylb, -(CH2)1.3-heteroaryl, -COOR12, -CONR12R13, -(CH2)i.3-NR14R15, CF3 and NR12R13; arylb is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13 heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i-3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and NR12R13; heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; wherein heteroarylb may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i-3-aryl, -COOR12, -CONR12R13, CF3 and NR12R13; R12 and R13 are independently selected from H and alkyl; or R12 and R13 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted; wherein, when R5, R6 and R7 are absent or H, then: either R10 and R11 together form a cycloalkyl ring or a cyclic ether; or A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1,2 or 3 substituents independently selected from OH, heteroaryl, arylb, -0-arylb, -(CH2)r3-arylb, -(CH2)i_3-heteroaryl, -COOR12, -CONR12R13, and -(CH2)3-NR14R15; wherein, arylb is phenyl, biphenyl or naphthyl, wherein arylb is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13; and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, -(CH2)i_3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and -NR12R13; or A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents independently selected from aryl, -(CH2)i-3-aryl, heteroarylb, -COOR12, and -CONR12R13;wherein, aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i-3-arylb, -(CH2)i_3-heteroaryl, -C00R12, -CONR12R13, -COR12R13, -(CH2)1.3-NR14R15, CF3 and -NR12R13; and heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroarylb is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i_3-aryl, -C00R12, -CONR12R13, CF3 and NR12R13; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect the present invention provides a prodrug of a compound of formula (I) as herein defined, or a pharmaceutically acceptable salt thereof.
In yet another aspect the present invention provides an N-oxide of a compound of formula (I) as herein defined, or a prodrug or pharmaceutically acceptable salt thereof.
It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms.
In an aspect the invention comprises a subset of the compounds of formula (I):
(l) wherein A, W, X, Y, Z, V, P, R1, R2, R3, R5, R6, R7, R8 and R9 are as defined above, with the proviso that at least one of R5, R6 and R7 must be present and be independently selected from alkyl, halo, aryl, heteroaryl and CF3; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In an aspect, the invention comprises a subset of the compounds of formula (I) wherein: R1 is H, F, Cl, CF3, OCH3orCH3; R2 is H or F if V is C; or R2 is absent if V is N; and R3 is H or CH3; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein: WisC; X is N;
YisC; Z is C; R5 is H; R6 and R7 are CH3; R8 and R9 are H; and R10 and R11 are both H or together form a cyclopropane ring; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein: WisC; X is N;
YisC; Z is C; R5 is H; R6 and R7 are CH3; R8 and R9 are both H; R10 and R11 are both H or together form a cyclopropane ring; and A is selected from:
/
// and
; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein: R1 is H, F, Cl, CF3, OCH3orCH3; R2 is H or F if V is C; or R2 is absent if V is N; and R3 is H or CH3;
WisC; X is N;
YisC; Z is C; R5 is H; R6 and R7 are CH3; R8 and R9 are both H; R10 and R11 are both H or together form a cyclopropane ring; and A is selected from:
/
//
and
; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein: VisC; R1 is H or CH3; R2 is H or F; R3 is H or CH3; W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; R5, R6 and R7 are independently absent, or are independently selected from H and alkyl; R8 and R9 are both H;
R10 and R11 together form a cyclopropane ring; and A is selected from:
,
, ,
, and
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein: VisC; R1 is H or CH3; R2 is Η; R3 is H or CH3; W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; R5, R6 and R7 are independently absent, or are independently selected from H, alkyl, halo, aryl, heteroaryl and CF3; R8 and R9 are both H; R10 and R11 are both H or together form a cyclopropane ring; and A is selected from:
, and
; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
In another aspect, the invention comprises a subset of the compounds of formula (I) wherein A is selected from:
, and
;
In an aspect, the invention comprises compounds of formula (II):
Formula (II) wherein, U and V are independently selected from C and N such that the aromatic ring containing U and V is phenyl, pyridine or pyrazine; R1 is absent when U is N; R2 is absent when V is N; or, when present, R1 and R2 are independently selected from H, alkyl, alkoxy, CN, halo and CF3; R3 is selected from H, alkyl, alkoxy, CN, halo and CF3; W, X, Y and Z are independently selected from C, N, O and S, such that the five-membered ring containing W, X, Y and Z is an aromatic heterocycle; R5, R6 and R7 are independently absent, or are independently selected from H, alkyl, halo, aryl, heteroaryl and CF3; or, optionally, when Y and/or Z is C, R5 and R6 may together form an aromatic ring, optionally containing 1 or 2 atoms selected from N, O or S, fused to the five-membered heterocyclic aromatic ring containing W, X, Y and Z; wherein the resulting aromatic fused bicycle may be optionally mono-, di- or tri-substituted with a substituent selected from alkyl, alkoxy, OH, halo, CN, -COOR12, -CONR12R13, CF3 and NR12R13; P and Q are, independently, H or-C(R10)(R11)NH2; R8 and R9 are independently selected from H and alkyl, or may together form a cycloalkyl ring; R10 and R11 are independently selected from H and alkyl, or may together form a cycloalkyl ring or a cyclic ether; L is a linker selected from a covalent bond, -(CH2)mo-, -0-(CH2)2-io-, -(CH2)i_i0-0-(CH2)i_io-, -(CH2)i.io-NH-(CH2)m0-, -CONH-(CH2)m0-, -CO-, and -S02-; A is selected from N-linked morpholine, aryl, and heteroaryl; alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (CrC6)alkoxy, OH, CN, CF3, -COOR12, -CONR12R13, H(CH2)1.3CON(R12)( CH^.s-, fluoro and -NR12R13; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms; wherein cycloalkyl may be optionally substituted with a substituent selected from alkyl, alkoxy and NR12R13; a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom; alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (CrC6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from aryl, OH, CN, CF3, -COOR12, -CONR12R13, fluoro and NR12R13; aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i.3-arylb, -(CH2)1.3-heteroaryl, -COOR12, -CONR12R13, -COR14R15, -(CH2)i_3-NR14R15, CF3 and NR12R13; arylb is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13 heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; heteroaryl may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)1.3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and NR12R13; heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; wherein heteroarylb may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i-3-aryl, -COOR12, -CONR12R13, CF3 and NR12R13; R12 and R13 are independently selected from H and alkyl; R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted; wherein, when R5, R6 and R7 are absent or H, then: either R10 and R11 together form a cycloalkyl ring or a cyclic ether; or A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1,2 or 3 substituents independently selected from OH, heteroaryl, arylb, -0-arylb, -(CH2)r3-arylb, -(CH2)i.3-heteroaryl, -COOR12, -CONR12R13, and -(CH2)3-NR14R15; wherein, arylb is phenyl, biphenyl or naphthyl, wherein arylb is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13; and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, -(CH2)i_3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and -NR12R13; or A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents independently selected from aryl, -(CH2)1.3-aryl, heteroarylb, -COOR12, and -CONR12R13;wherein, aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i-3-arylb, -(CH2)i.3-heteroaryl, -COOR12, -CONR12R13, -COR12R13, -(CH2)1.3-NR14R15, CF3 and -NR12R13; and heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroarylb is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)1.3-aryl, -C00R12, -CONR12R13, CF3 and NR12R13; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.
The present invention also comprises the following aspects and combinations thereof: V is selected from C and N such that the aromatic ring containing V is phenyl or pyridine.
In an embodiment, V is N such that the aromatic ring containing V is pyridine.
In an embodiment, V is C such that the aromatic ring containing V is phenyl.
In a preferred embodiment U is C. R2 is absent when V is N. R1 and, when present, R2 are independently selected from H, alkyl, alkoxy, CN, halo and CF3. In an embodiment, R1 and, when present, R2 are independently selected from H, alkyl, alkoxy, halo and CF3.
In an embodiment, R1 and, when present, R2 are independently selected from H, methyl, methoxy, Cl, F and CF3.
In an embodiment, R1 is selected from H, methyl, methoxy, Cl, F and CF3.
In an embodiment, R1 is selected from alkyl, alkoxy, CN, halo and CF3.
In a preferred embodiment, R1 is selected from H and methyl.
In a more preferred embodiment, R1 is H.
In an embodiment, when present, R2 is selected from H, methyl, methoxy, and F.
In a preferred embodiment, when present, R2 is H. R3 is selected from H, alkyl, alkoxy, CN, halo and CF3;
In an embodiment, R3 is selected from H and alkyl.
In a preferred embodiment, R3 is selected from H and methyl.
In a more preferred embodiment, R3 is H.
In an embodiment, when R2 is present, R1 is selected from H, methyl, methoxy, Cl, F and CF3; R2 is H; and R3 is selected from H and methyl.
In an embodiment, R2 is present and R1, R2 and R3 are H.
In an embodiment, R1 and R3 are methyl.
In an embodiment, when R2 is present, R1 and R3 are methyl; and R2 is H.
In a preferred embodiment, R1 is methyl. W, X, Y and Z are independently selected from C, N, O and S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle.
In an embodiment, W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle.
In an embodiment, W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is selected from pyrrole, pyrazole, imidazole, 1, 2, 3-triazole and 1, 2, 4-triazole.
In a preferred embodiment, X is N.
In an embodiment, W is C, X and Y are N and Z is C or N.
In an embodiment, X and Y are N and W and Z are C.
In an embodiment, X, Y and Z are N and W is C.
In a more preferred embodiment, X is N and W, Y and Z are C. R5, R6 and R7 are independently absent, or are independently selected from H, alkyl, halo, aryl, heteroaryl and CF3.
In an embodiment, R5 is absent or is selected from H, alkyl, CF3 and aryl.
In an embodiment, R5 is absent or is selected from H, methyl CF3 and phenyl.
In a preferred embodiment R5 is H.
In an embodiment, R6 and R7 are independently absent, or are independently selected from H, alkyl, aryl and CF3.
In an embodiment, R6 and R7 are independently absent, or are independently selected from H, methyl, ethyl, n-propyl, phenyl and CF3.
In a preferred embodiment, R6 and R7 are methyl.
In an embodiment, X and Y are N, W and Z are C, and R5 and R7 are H.
In an embodiment, X, Y and Z are N, W is C, and R7 is H.
In a preferred embodiment, X is N, W, Y and Z are C, R5 is H and R6 and R7 are methyl. R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted.
In a preferred embodiment, P is -C(R10)(R11)NH2 and Q is H. R8 and R9 are independently selected from H and alkyl, or may together form a cycloalkyl ring. In an embodiment, R8 and R9 are independently selected from H and alkyl, or may together form a cyclopropyl ring.
In an embodiment, R8 and R9 are independently selected from H and methyl, or may together form a cyclopropyl ring.
In a preferred embodiment, R8 and R9 are H. R10 and R11 are independently selected from H and alkyl, or may together form a cycloalkyl ring or a cyclic ether.
In an embodiment, R10 and R11 are independently selected from H and alkyl, or may together form a cyclopropyl ring.
In an embodiment, R10 and R11 are independently selected from H and methyl, or may together form a cyclopropyl ring.
In a preferred embodiment, R10 and R11 are H.
In a preferred embodiment, L is methylene. A is selected from N-linked morpholine, aryl, and heteroaryl.
In an embodiment, A is selected from aryl, and heteroaryl.
In an embodiment, A is selected from:
I
I i
J
J J
,
, and
.
In an embodiment A is selected from:
j j j and
.
In an embodiment, A is selected from:
J J J
, and
.
In an aspect, R5, R6 and R7 are absent or H; and A is selected from:
and
.
In a preferred aspect, A is:
In an aspect, the invention comprises a compound selected from: 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-(l-amino-cyclopropyl)-benzylamide; 2.5- Dimethyl-1-(6-phenyl-pyridin-2-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 1-[2-(3-Fluoro-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-(2-thiophen-3-yl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid (6-aminomethyl-pyridin-3-ylmethyl)-amide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-fluoro-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-chloro-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-trifluoromethyl-benzylamide; 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methoxy-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1-[4-(3,5-Dimethyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 2.5- Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4- aminomethyl-2,6-dimethyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide; 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide; 5- Methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-2-methyl-benzylamide; 3-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 5-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-(2-Methyl-quinolin-6-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-(2-Pyrrolidin-1-yl-pyridin-4-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; and pharmaceutically acceptable salts and solvates thereof.
Therapeutic Applications
As previously mentioned, the compounds of the present invention are potent and selective inhibitors of plasma kallikrein. They are therefore useful in the treatment of disease conditions for which over-activity of plasma kallikrein is a causative factor.
Accordingly, the present invention provides a compound of formula (I) for use in medicine.
The present invention also provides for the use of a compound of formula (I) in the manufacture of a medicament for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
The present invention also provides a compound of formula (I) for use in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
The present invention also provides a method of treatment of a disease or condition in which plasma kallikrein activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I).
In one aspect, the disease or condition in which plasma kallikrein activity is implicated is selected from diseases or conditions in which plasma kallikrein activity is implicated include impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammaotory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery.
In a preferred aspect, the disease or condition in which plasma kallikrein activity is implicated is retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
Combination Therapy
The compounds of the present invention may be administered in combination with other therapeutic agents. Suitable combination therapies include a compound of formula (I) combined with one or more agents selected from agents that inhibit platelet-derived growth factor (PDGF), endothelial growth factor (VEGF), integrin alpha5beta1, steroids, other agents that inhibit plasma kallikrein and other inhibitors of inflammation. Specific examples of therapeutic agents that may be combined with the compounds of the present invention include those disclosed in EP2281885A and by S. Patel in Retina, 2009 Jun;29(6 Suppl):S45-8.
When combination therapy is employed, the compounds of the present invention and said combination agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
In another aspect, the compounds of the present invention may be administered in combination with laser treatment of the retina. The combination of laser therapy with intravitreal injection of an inhibitor of VEGF for the treatment of diabetic macular edema is known (Elman M, Aiello L, Beck R, et al. “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema” .Ophthalmology. 27 April 2010).
Definitions
The term "alkyl" includes saturated hydrocarbon residues including: - linear groups up to 10 carbon atoms (C1-C10), or of up to 6 carbon atoms (CrC6), or of up to 4 carbon atoms (C1-C4). Examples of such alkyl groups include, but are not limited, to C1 -methyl, C2 - ethyl, C3 - propyl and C4- n-butyl. - branched groups of between 3 and 10 carbon atoms (C3-C10), or of up to 7 carbon atoms (C3-C7), or of up to 4 carbon atoms (C3-C4). Examples of such alkyl groups include, but are not limited to, C3 - iso-propyl, C4 - sec-butyl, C4 - iso-butyl, C4 - tert-butyl and C5 - neo-pentyl. each optionally substituted as stated above.
The term "alkoxy" includes O-linked hydrocarbon residues including: - linear groups of between 1 and 6 carbon atoms (CrC6), or of between 1 and 4 carbon atoms (C1-C4). Examples of such alkoxy groups include, but are not limited to, C1 -methoxy, C2 - ethoxy, C3 - n-propoxy and C4 - n-butoxy. - branched groups of between 3 and 6 carbon atoms (C3-C6) or of between 3 and 4 carbon atoms (C3-C4). Examples of such alkoxy groups include, but are not limited to, C3 - iso-propoxy, and C4 - sec-butoxy and tert-butoxy. each optionally substituted as stated above.
Unless otherwise stated, halo is selected from Cl, F, Br and I.
Cycloalkyl is as defined above. Cycloalkyl may be substituted with a substituent selected from those stated above. Cycloalkyl groups may contain from 3 to 7 carbon atoms, or from 3 to 6 carbon atoms, or from 3 to 5 carbon atoms, or from 3 to 4 carbon atoms. Examples of suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
Aryl is as defined above. Typically, aryl will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl groups include phenyl and naphthyl (each optionally substituted as stated above). Preferably aryl is selected from phenyl, substituted phenyl (substituted as stated above) and naphthyl.
Heteroaryl is as defined above. Examples of suitable heteroaryl groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl and isoquinolinyl (optionally substituted as stated above). Preferably heteroaryl is selected from pyridyl, benzothiazole, indole, N-methylindole, thiazole, substituted thiazole, thiophenyl, furyl, pyrazine, pyrazole, substituted pyrazole, quinolone and substituted quinolone; wherein substituents are as stated above.
The term "N-linked", such as in "N-linked morpholine", means that the morpholinyl group is joined to the remainder of the molecule via a ring nitrogen atom.
The term "O-linked", such as in "O-linked hydrocarbon residue", means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
In groups such as -COOR12,"-" denotes the point of attachment of the substituent group to the remainder of the molecule. "Pharmaceutically acceptable salt" means a physiologically or toxicologically tolerable salt and includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts. For example (i) where a compound of the invention contains one or more acidic groups, for example carboxy groups, pharmaceutically acceptable base addition salts that can be formed include sodium, potassium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, /V-methyl-glucamine, diethanolamine or amino acids (e.g. lysine) and the like; (ii) where a compound of the invention contains a basic group, such as an amino group, pharmaceutically acceptable acid addition salts that can be formed include hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tosylates, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, camphorates, xinafoates, p-acetamidobenzoates, di hydroxy benzoates, hydroxynaphthoates, succinates, ascorbates, oleates, bisulfates and the like.
Hemisalts of acids and bases can also be formed, for example, hemisulfate and hemicalcium salts.
For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). “Prodrug” refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in The Practice of Medicinal Chemistry, 2nd Ed. pp561-585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379.
The compounds of the invention can exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when the solvent is water.
Where compounds of the invention exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and trans-forms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis).
In the context of the present invention, references herein to "treatment" include references to curative, palliative and prophylactic treatment.
General Methods
The compounds of formula (I) should be assessed for their biopharmaceutical properties, such as solubility and solution stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed indication. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term ’excipient’ is used herein to describe any ingredient other than the compound(s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Compounds of the invention intended for pharmaceutical use may be administered as a solid or liquid, such as a tablet, capsule or solution. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington’s Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
Accordingly, the present invention provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, diluent or excipient.
For the treatment of conditions such as retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema, the compounds of the invention may be administered in a form suitable for injection into the ocular region of a patient, in particular, in a form suitable for intra-vitreal injection. It is envisaged that formulations suitable for such use will take the form of sterile solutions of a compound of the invention in a suitable aqueous vehicle. The compositions may be administered to the patient under the supervision of the attending physician.
The compounds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, manitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of cosolvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
In one embodiment, the compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semisolid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
Formulations suitable for oral administration may also be designed to deliver the compounds of the invention in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds. Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with the said compounds to control their release.
Examples of rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion. Examples of rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
Liquid (including multiple phases and dispersed systems) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
The formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.01 mg and 1000 mg, or between 0.1 mg and 250 mg, or between 1 mg and 50 mg depending, of course, on the mode of administration.
The total dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
Synthetic Methods
The compounds of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples provided herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
The compounds of the invention may be isolated in the form of their pharmaceutically acceptable salts, such as those described previously herein above.
It may be necessary to protect reactive functional groups (e.g. hydroxy, amino, thio or carboxy) in intermediates used in the preparation of compounds of the invention to avoid their unwanted participation in a reaction leading to the formation of the compounds. Conventional protecting groups, for example those described by T. W. Greene and P. G. M. Wuts in “Protective groups in organic chemistry” John Wiley and Sons, 4th Edition, 2006, may be used. For example, a common amino protecting group suitable for use herein is tert-butoxy carbonyl (Boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane. Alternatively the amino protecting group may be a benzyloxycarbonyl (Z) group which can be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere or 9-fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by solutions of secondary organic amines such as diethylamine or piperidine in an organic solvents. Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide. Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively a trichloroethyl ester protecting group is removed with zinc in acetic acid. A common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr for 1-24 hours, or by stirring with borane tribromide in dichloromethane for 1-24 hours. Alternatively where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.
The compounds according to general formula I can be prepared using conventional synthetic methods for example, but not limited to, the route outlined in Scheme 1. In a typical first step the amine 2 is coupled to an acid 1 using standard coupling condition such as hydroxybenzotriazole and carbodiimide such as water soluble carbodiimide in the presence of an organic base. Other standard coupling methods include the reaction of acids with amines in the presence of 2-(1 H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate or benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoium hexaffluorophosphate or bromo-trispyrolidino-phosphoium hexafluorophosphate in the presence of organic bases such as triethylamine, N,N-diisopropylethylamine or N-methylmorpholine. Alternatively the amide formation can take place via an acid chloride in the presence of an organic base. Such acid chlorides can be formed by methods well known in the literature, for example reaction of the acid with oxalyl chloride or thionyl chloride.
The route exemplified in Scheme 1 then proceeds in the third step involving reduction of a nitrile. Reduction of compound 3 to compound 5 may be achieved in a single step by reduction with a suitable borohydride in the presence of a suitable transition metal such as cobalt or nickel chloride in a suitable solvent such as methanol at room temperature, alternatively this may be achieved in a single step by direct reduction of the nitrile by hydrogenation in a suitable solvent such as methanol in the presence of a suitable catalyst such as palladium on charcoal in the presence of an acid such as hydrochloric acid to yield the amine 5. In the exemplified scheme the te/f-butoxycarbonyl (Boc) protected amine 4 may be isolated (using, for example, the method as described in S. Caddick et al., Tetrahedron Lett., 2000, 41, 3513) and subsequently deprotected by standard means described previously to give the amine 5.
Scheme 1
Alternatively compounds according to general formula I can be prepared using the route exemplified in Scheme 2. The acid 1 can be coupled to an amine 6 using suitable coupling methods as previously described to give Compound 7 in which the second amino group is amino-protected with a standard protecting group such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Z) or 9-fluorenylmethyloxycarbonyl (Fmoc). In a typical second step the protecting group is removed to give compound 5 using standard methods as previously described.
Scheme 2
Alternatively compounds according to general formula I can be prepared using the route outlined in Scheme 3. The acid 8 can be coupled to an amine 6 using suitable coupling methods as previously described to give compound 9 in which the second amino group is amino-protected with a standard protecting group such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Z) or 9-fluorenylmethyloxycarbonyl (Fmoc). In a typical second step the nitrogen of the heterocyclic ring is alkylated with compound 10 to give compound 11. The alkylation can be carried out in the presence of a base such as potassium carbonate, cesium carbonate, sodium carbonate or sodium hydride in which case the leaving group is a halide or sulphonate. Alternatively the alkylation may be carried out using an alcohol under Mitsunobu conditions in the presence of triphenylphosphine. In a third step the protecting group is removed to give compound 12 using standard methods as previously described.
Scheme 3
Alternatively compounds according to general formula I can be prepared using the route outlined in Scheme 4. The pyrrole 17 can be formed in two steps the first of which involves reaction of the sodium salt of an alkyl ketoacetate 13 with a chloroketone 14 in the presence of a base such as potassium carbonate to give compound 15 which in a typical second step is reacted with the amine 16 in the presence of an acid such as but not limited to sulphonic acid derivatives e.g. p-toluenesulphonic acid to yield compound 17 which in a typical third step is subsequently hydrolysed to the corresponding acid 18 using standard methods as described previously. In a typical fourth step the acid 18 can be coupled to an amine 6 using suitable coupling methods as previously described to give compound 19 in which the second amino group is amino-protected with a standard protecting group such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Z) or 9-fluorenylmethyloxycarbonyl (Fmoc). In a typical final step the protecting group is removed to give compound 20 using standard methods as previously described.
Scheme 4
Alternatively compounds according to general formula I can be prepared using the route outlined in Scheme 5. The triazole 22 can be formed by reaction of an alkyl propiolate with the azide 21 under azide alkyne Huisgen cycloaddition conditions employing a catalyst such as copper salts with abscorbic acid derivatives. In a typical second step the ester is hydrolysed to the corresponding acid 23 using standard methods as described previously. In a typical third step the acid 23 can be coupled to an amine 6 using suitable coupling methods as previously described to give compound 24 in which the second amino group is amino-protected with a standard protecting group such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Z) or 9-fluorenylmethyloxycarbonyl (Fmoc). In a typical final step the protecting group is removed to give compound 25 using standard methods as previously described.
Scheme 5
Alternatively compounds according to general formula I can be prepared using the route outlined in Scheme 6. The imidazole 26 can be formed by reaction of the acrylate derivative 26 with the amine 16 in the presence of organic bases such as Ν,Ν-diisopropylethylamine or triethylamine. In a typical second step the ester is hydrolysed to the corresponding acid 28 using standard methods as described previously. In a typical third step the acid 28 can be coupled to an amine 6 using suitable coupling methods as previously described to give compound 29 in which the second amino group is amino-protected with a standard protecting group such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Z) or 9-fluorenylmethyloxycarbonyl (Fmoc). In a typical final step the protecting group is removed to give compound 30 using standard methods as previously described.
Scheme 6
Alternatively compounds according to general formula I can be prepared using the route outlined in Scheme 7. In a typical first step the nitrogen of the heterocyclic ring is derivatised by reaction of compound 9 with the sulphonyl chloride 31 in the presence of organic bases such as Ν,Ν-diisopropylethylamine or triethylamine to give compound 32. In a typical final step the protecting group is removed to give compound 33 using standard methods as previously described.
Scheme 7
The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:
All reactions were carried out under an atmosphere of nitrogen unless specified otherwise. 1H NMR spectra were recorded on a Bruker Avance III (400MHz) spectrometerwith reference to deuterium solvent and at room temperature.
Molecular ions were obtained using LCMS which was carried out using a Chromolith Speedrod RP-18e column, 50 x 4.6 mm, with a linear gradient 10% to 90% 0.1% HC02H/MeCN into 0.1% HC02H/H20 over 11 min, flow rate 1.5 mL/min. Data was collected using a Thermofinnigan Surveyor MSQ mass spectrometerwith electospray ionisation in conjunction with a Thermofinnigan Surveyor LC system.
Chemical names were generated using the Autonom software provided as part of the ISIS Draw package from MDL Information Systems.
Where products were purified by flash chromatography, ‘silica’ refers to silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Merck silica gel 60), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution. Reverse phase preparative HPLC purifications were carried out using a Waters 2525 binary gradient pumping system at flow rates of typically 20ml/min using a Waters 2996 photodiode array detector.
All solvents and commercial reagents were used as received.
COMPOUND A 4-Bromo-2-fluoro-3-methyl-benzonitrile
To a solution of diisopropylamine (4.2ml_, 30mmol) in dry THF (5ml) was added a solution of nBuLi in THF (2.5M, 11ml_, 27.5mmol) dropwise at-78 °C. Once addition was complete, the reaction was allowed to warm to 0 °C and stirred in an ice-salt bath for 40 mins. The resulting solution was added dropwise to a solution of 4-bromo-2-fluorobenzonitrile (5g, 25mmol) in dry THF (50ml) at -78 °C and the mixture stirred for 2.5 hrs. The reaction mixture was then cooled to -78 °C and methyl iodide added in one portion and the mixture slowly allowed to warm to room temperature. The reaction was quenched with aqueous NH4CI and extracted with EtOAc (3x 40ml). The combined organics were washed with water (40ml) and brine (40ml). The organics were dried over MgS04, filtered and concentrated. The residue was purified by column chromatography eluting with 9:1 pet ether: ethyl acetate to afford 4-bromo-2-fluoro-3-methyl-benzonitrile as an off white solid (2.40g, 45% yield).
COMPOUND B 4-Bromo-2-fluoro-3,5-dimethvl-benzonitrile
Following a similar procedure to that described for the preparation of Compound A, 4-bromo-2-fluoro-3-methyl-benzonitrile was converted to 4-bromo-2-fluoro-3,5-dimethyl-benzonitrile which was isolated as a lime green oil. EXAMPLE 1 2.5-Dimethvl-1 -(2-phenyl-thiazol-4-vlmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide
A. 2-Acetyl-4-oxo-pentanoic acid ethyl ester
Ethylacetoacetate sodium salt (17.10g, 112mmol) was suspended in acetone (500mls) Potassium carbonate (15.54g, 112mmol) and potassium iodide (3.73g, 22.48mmol) were added and the resulting solution was refluxed. Chloroacetone (11.41 g, 124mmol) was added dropwise over a period of 5 mins). Once the addition was complete the mixture was heated under reflux for a further 2 hours. The reaction mixture was allowed to cool to room temperature and the solid material was filtered off and washed with acetone. The resultant filtrate was evaporated and purified by flash chromatography (silica), eluant 75% Pet. Ether (60-80°C), 25% EtOAc, fractions combined and evaporated in vacuo to give a yellow oil identified as 2-acetyl-4-oxo-pentanoic acid ethyl ester (10.1 g, 54.2mmol, 48%). B. 1-[2-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester 2-Acetyl-4-oxo-pentanoic acid ethyl ester (1.8g, 9.66mmol) was dissolved in toluene (35mls), 2-phenyl-thiazoyl-4-methylamine (2.02g, 10.62mmol) and p-toluenesulphonic acid (183mg, 0.966mmol) were added. The reaction mixture was heated at reflux for 4 hours after which time it was diluted with ethyl acetate and washed with NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 85% Pet. Ether (60-80°C), 15% EtOAc, fractions combined and evaporated in vacuo to give a colourless oil identified as 1-[2-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1.26g, 3.69mmol, 38%).
[M+H]+ = 341.27 C. 2,5-Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 1-[2-Phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1.07g, 3.14mmol) was dissolved in ethanol (50mls). Sodium hydroxide (629mg, 15.72mmol) in water (5mls) was added. The reaction mixture was heated at 90°C for 3 days after which time the solvent was removed in vacuo. The residue was diluted with water and acidified to pH 1 with 1M HCI and extracted with ethyl acetate (3x 50mls). The combined extracts were washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give an off white solid identified as 2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (980mg, 3.14mmol, 100%).
[M+H]+ = 313.23 D. [4-({[2,5-Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (1.60g, 5.12mmol) was dissolved in CH2CI2(100mls) and DMF(5mls). This solution was cooled to 0°C. 1-(N-Boc-aminomethyl)-4-(aminomethyl) benzene (1.21 g, 5.12mmol) was added followed by HOBt (830mg, 6.14mmol) and triethylamine (2.59g, 25.6mmol). Water soluble carbodiimide (1.37g, 4.33mmol) was then added. After 18 hrs at 0°C to room temperature reaction mixture was diluted with chloroform (200mls) and washed with NaHC03 (1x50mls), water (1x50mls), brine (1x50mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 50%Pet. Ether (60-80°C), 50% EtOAc, fractions combined and evaporated in vacuo to give a white solid identified as [4-({[2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester (2.30g, 4.33mmol, 85%).
[M+H]+ = 531.29. E. 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide [4-({[2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester (2.30g, 4.33mmol) was dissolved in methanol (40mls) to which 4M HCI in dioxan (10mls) was added. After three hours at room temperature the solvent was removed in vacuo and the residue was azeotroped from toluene. The free base was liberated with a mixture of dichloromethane, MeOH and NH3 then evaporated. The residue was purified by flash chromatography (silica), eluant dichlromethane:MeOH:NH3 (100:10:1). The residue was triturated with EtOAc/Pet Ether 60-80°C to give an off white solid identified as 2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide (1.2g, 2.79mmol, 64%).
[M+H]+ = 431.20 1H NMR: (d6-DMSO), δ: 2.26(3H,s), 2.56(3H,s), 3.33(2H,br s), 3.68(2H,s), 4.33(2H,d,J= 6.1Hz), 5.17(2H,s), 6.29(1 H,s), 7.19-7.26(5H,m), 7.48(3H,m), 7.90-7.92(2H,m), 8.05(1 H,t,J= 6.1Hz). EXAMPLE 2 2.5-Dimethvl-1 -(2-phenyl-thiazol-4-vlmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide
A. (4-Cyano-2-methyl-benzyl)-carbamic acid benzyl ester 4-Aminomethyl-3-methylbenzonitrile (1.0g, 5.48mmol) was dissolved in dichloromethane (50mls) and the solution was cooled to 0°C. Ν,Ν-Diisopropylethylamine (1.56g, 12.05mmol) was added followed by benzyl chloroformate 1.12g, 6.57mmol) was added. After 3 days at 0°C to room temperature the reaction mixture was diluted with chloroform, this solution was washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a brown oil identified as (4-cyano-2-methyl-benzyl)-carbamic acid benzyl ester (1.50g, 5.35mmol, 98%).
[M+H]+ = 281.25 B. [4-(tert-Butoxycarbonylamino-methyl)-2-methyl-benzyl]-carbamic acid benzyl ester (4-Cyano-2-methyl-benzyl)-carbamic acid benzyl ester (1.5g, 5.35mmol) was dissolved in methanol (75mls). This solution was cooled to 0°C. Nickel (II) chloride hexahydrate (127mg, 0.54mmol) and di-tertbutyl dicarbonate (2.34g, 10.70mmol) were added followed by sodium borohydride (1.42g, 37.56mmol) portionwise. The reaction mixture was stirred at 0°C to room temp for 3 days. The MeOH was removed by evaporation. The residue was dissolved in CHCI3 (70mls), washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a yellow oil. Purified by flash chromatography, (silica), eluant 40%Pet. Ether (60-80°C), 60% EtOAc to give white solid identified as [4-(tert-butoxycarbonylamino-methyl)-2-methyl-benzyl]-carbamic acid benzyl ester (1.11g, 2.38mmol, 54%).
[M+H]+ = 285.32. C. (4-Aminomethyl-3-methyl-benzyl)-carbamic acid tert-butyl ester
[4-(tert-Butoxycarbonylamino-methyl)-2-methyl-benzyl]-carbamic acid benzyl ester (130mg, 0.34mmol) was dissolved in methanol (40mls). This solution was hydrogenated over 10% Pd/C (40mg) at atmospheric pressure and room temperature for one hour after which time the catalyst was filtered off and washed with methanol (30mls), the combined filtrates were evaporated in vacuo to give a white solid identified as (4-aminomethyl-3-methyl-benzyl)-carbamic acid tert-butyl ester (80mg, 0.32mmol, 95%). D. [4-({[2,5-Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-3-methyl-benzyl]-carbamic acid tert-butyl ester 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (100mg, 0.32mmol) was dissolved in CH2CI2(20mls). This solution was cooled to 0°C. (4-Aminomethyl-3-methyl-benzyl)-carbamic acid tert-butyl ester (80mg, 0.32mmol) was added followed by HOBt (52mg, 0.38mmol) and triethylamine (162mg, 1.60mmol). Water soluble carbodiimide (86mg, 0.45mmol) was then added. After 18 hrs at 0°C to room temperature reaction mixture was diluted with chloroform (200mls) and washed with NaHC03 (1x50mls), water (1x50mls), brine (1x50mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 50% Pet. Ether (60-80°C), 50% EtOAc, fractions combined and evaporated in vacuo to give a white solid identified as [4-({[2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-3-methyl-benzyl]-carbamic acid tert-butyl ester (105mg, 0.19mmol, 60%).
[M+H]+ = 567.14. E. 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide [4-({[2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-3-methyl-benzyl]-carbamic acid tert-butyl ester (105mg, 0.93mmol) was dissolved in methanol (20mls) to which 4M HCI in dioxan (5mls) was added. After three hours at room temperature the solvent was removed in vacuo and the residue was azeotroped from toluene. The free base was liberated with a mixture of dichloromethane, MeOH and NH3 then evaporated. The residue was purified by flash chromatography (silica), eluant dichlromethane:MeOH:NH3 (100:10:1). The residue freeze dried from acetonitrile and water to give an off white solid identified as 2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide (58mg, 0.13mmol, 68%).
[M+H]+ = 445.17 1H NMR: (d6-DMSO), δ: 2.26(3H,s), 2.27(3H,s), 2.55(3H,s), 3.32(2H,br s), 3.65(2H,s), 4.30(2H,s), 5.16(21-1,s), 6.31(1H,s), 7.08-7.13(3H,m), 7.27(1H,s), 7.48-7.54(3H,m), 7.87-7.92(3H,m). EXAMPLE 3 2.5- Dimethvl-1 -(2-phenyl-thiazol-4-vlmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl- 2.6- dimethyl-benzylamide
A. (4-Bromo-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester 4-Bromo-2,6-dimethylbenzonitrile (2.5g, 11.9mmol) was dissolved in methanol (150mls). This solution was cooled to 0°C. Nickel (II) chloride hexahydrate (238mg, 1.19mmol) and di-tertbutyl dicarbonate (5.19g, 23.80mmol) were added followed by sodium borohydride (3.15g, 83.30mmol) portionwise. The reaction mixture was stirred at 0°C to room temp for 3 days. The MeOH was removed by evaporation. The residue was dissolved in CHCI3 (70mls), washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a colourless oil identified as (4-bromo-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester (3.0g, 9.55mmol, 80%). B. (4-Cyano-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester
To a degassed solution of (4-bromo-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester (3.0g, 9.55mmol) in Ν,Ν-dimethylacetamide (30mls) was added zinc powder (75mg, 1.15mmol), zinc acetate (210mg, 1.15mmol), 1,1'-bis(diphenylphosphino) ferrocine (635mg, 1.15mmol), zinc cyanide (560mg, 4.77mmol), and tris(dibenzylideneacetone) dipalladium(O) (524mg, 0.57mmol). The reaction was heated at 120°C for 4 hrs. After which the reaction mixture was cooled to room temperature and extra 1,1'-bis(diphenylphosphino) ferrocine (423mg, 0.77mmol) and tris(dibenzylideneacetone) dipalladium(O) (350mg, 0.38mmol) were added and the reaction was heated at 120°C for a further 28 hrs. The reaction mixture was cooled to RT filtered through celite and washed with ethyl acetate (250 mis). The filtrate washed with sat NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography, (silica), eluant 80%Pet. Ether (60-80°C), 20% EtOAc to give an off white solid identified as (4-cyano-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester (630mg, 2.42mmol, 25%).
[M+H]+ = 261.06. C. 4-Aminomethyl-3,5-dimethyl-benzonitrile Hydrochloride (4-Cyano-2,6-dimethyl-benzyl)-carbamic acid tert-butyl ester (630mg, 2.42mmol) was dissolved in 4M HCI in dioxan (10mls). After one hour at room temperature the solvent was removed in vacuo to give a pale brown solid identified as 4-aminomethyl-3,5-dimethyl-benzonitrile hydrochloride (470mg, 2.39mmol, 99%). D. (4-Cyano-2,6-dimethyl-benzyl)-carbamic acid benzyl ester 4-Aminomethyl-3,5-dimethyl-benzonitrile hydrochloride (470mg, 2.39mmol) was dissolved in dichloromethane (50mls) and the solution was cooled to 0°C. N,N-Diisopropylethylamine (679mg, 5.26mmol) was added followed by benzyl chloroformate (489mg, 2.87mmol) was added. After one hour at 0°C to room temperature the reaction mixture was diluted with chloroform, this solution was washed with sat NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a brown oil identified as (4-cyano- 2,6-dimethyl-benzyl)-carbamic acid benzyl ester (700mg, 2.38mmol, 99%).
[M+H]+ = 295.04 E. [4-(tert-Butoxycarbonylamino-methyl)-2,6-dimethyl-benzyl]-carbamic acid benzyl ester (4-Cyano-2,6-dimethyl-benzyl)-carbamic acid benzyl ester (700mg, 2.38mmol) was dissolved in methanol (75mls). This solution was cooled to 0°C. Nickel (II) chloride hexahydrate (57mg, 0.24mmol) and di-tertbutyl dicarbonate( 1.04g, 4.76mmol) were added followed by sodium borohydride (630mg, 16.65mmol) portionwise. The reaction mixture was stirred at 0°C to room temp for 3 days. The MeOH was removed by evaporation. The residue was dissolved in CHCI3 (70ml), washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography, (silica), eluant 65%Pet. Ether (60-80°C), 35% EtOAc to give an off white solid identified as [4-(tert-butoxycarbonylamino-methyl)-2,6-dimethyl-benzyl]-carbamic acid benzyl ester (600mg, 1.51 mmol, 63%).
[M+H]+ = 421.05 (M+Na). F. (4-Aminomethyl-3,5-dimethyl-benzyl)-carbamic acid tert-butyl ester [4-(tert-Butoxycarbonylamino-methyl)-2,6-dimethyl-benzyl]-carbamic acid benzyl ester (600mg, 1.51 mmol) was dissolved in methanol (60mls). This solution was hydrogenated over 10% Pd/C (100mg) at atmospheric pressure and room temperature for one hour after which time the catalyst was filtered off and washed with methanol (30mls), the combined filtrates were evaporated in vacuo to give a white solid identified as (4-aminomethyl-3,5-dimethyl-benzyl)-carbamic acid tert-butyl ester (350mg, 1.32mmol, 88%). G. [4-({[2,5-Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-3,5-dimethyl-benzyl]-carbamic acid tert-butyl ester 2.5- Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (118mg, 0.38mmol) was dissolved in CH2CI2(20mls). This solution was cooled to 0°C. (4-(4-Aminomethyl-3,5-dimethyl-benzyl)-carbamic acid tert-butyl ester (100mg, 0.38mmol) was added followed by HOBt (61mg, 0.45mmol) and triethylamine (191mg, 1.89mmol). Water soluble carbodiimide (102mg, 0.53mmol) was then added. After 18 hrs at 0°C to room temperature reaction mixture was diluted with chloroform (200mls) and washed with NaHC03 (1x50mls), water (1x50mls), brine (1x50mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 50% Pet. Ether (60-80°C), 50% EtOAc, fractions combined and evaporated in vacuo to give a white solid identified as [4-({[2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-3,5-dimethyl-benzyl]-carbamic acid tert-butyl ester (110mg, 0.20mmol, 52%).
[M+H]+ = 567.14. H. 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide [4-({[2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-3,5-dimethyl-benzyl]-carbamic acid tert-butyl ester (110mg, 0.20mmol) was dissolved in methanol (20mls) to which 4M HCI in dioxan (5mls) was added. After three hours at room temperature the solvent was removed in vacuo and the residue was azeotroped from toluene. The free base was liberated with a mixture of dichloromethane, MeOH and NH3 then evaporated. The residue was purified by flash chromatography (silica), eluant dichloromethane:MeOH:NH3 (100:10:1). The residue freeze dried from acetonitrile and water to give an off white solid identified as 2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide (77mg, 0.17mmol, 85%).
[M+H]+ = 459.09 1H NMR: (d6-DMSO), δ: 2.22(3H,s), 2.34(6H,s), 2.54(3H,s), 3.74(2H,s), 4.34(2H,d,J= 5.0Hz), 5.15(2H,s), 5.44(2H,br s), 6.24(1H,s), 7.00(2H,s), 7.25(1H,s), 7.45(1H,t,J= 5.1Hz), 7.49-7.51(3H,m), 7.88-7.91(2H,m). EXAMPLE 4 2.5- Dimethvl-1-(2-phenvl-thiazol-4-vlmethvl)-1H-pyrrole-3-carboxvlic acid 4-(1-amino-cyclopropvD-benzylamide
A. 4-(1 -Amino-cyclopropyl)-benzonitrile
In oven dried glassware under an atmosphere of nitrogen a solution of 1,4-dicyanobenzene (2.50g, 20mmol) in anhydrous dichloromethane (80mls) was cooled to -70°C. Titanium isopropoxide (6.1 g, 21.46 mmol) was added followed by dropwise addition of 3M solution of ethyl magnesium bromide in diethyl ether (14.37mls, 43mmol). The reaction was stirred at -70°C for 10 min and then allowed to warm to room temperature). After 1 hour boron trifluoride etherate (5.54g, 39.02mmol) was added and the reaction stirred at room temperature for 18 hours. The reaction was quenched with NH4CI and then the pH adjusted to 9-10 with 1M NaOH. The layers were separated and the aqueous extracted dichloromethane (5 x 20 mis) then with ethyl acetate (3 x 20mls). Organic layers were combined and dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography (silica), eluant dichloromethane/MeOH/NH4OH (99:1:1, 98:2:1, 97:3:1, 95:5:1) giving a yellow oil identified as 4-(1-amino-cyclopropyl)-benzonitrile (1.61 g, 10mmol, 52%). 1H NMR: (CDCIs), δ: 1.07 - 1.10 (2H, m), 1.21 - 1.24 (2H, m), 1.86 (2H, br,s), 7.39 (2H, dt, J = 8.4, 1.9 Hz), 7.61 (2H, dt, J = 8.4, 1.9 Hz). B. [1-(4-Cyano-phenyl)-cyclopropyl]-carbamic acid benzyl ester 4-(1-Amino-cyclopropyl)-benzonitrile (1.61 g, 10.18mmol) was dissolved in dichloromethane (250mls) and the solution was cooled to 0°C. Ν,Ν-Diisopropylethylamine (2.89g, 22.39mmol) was added followed by benzyl chloroformate 2.08g, 12.21 mmol) was added. After 18 hours at 0°C to room temperature the reaction mixture was diluted with chloroform, this solution was washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 90%Pet. Ether (60-80°C), 10% EtOAc, fractions combined and evaporated in vacuo to give a to give a yellow oil identified as [1-(4-cyano-phenyl)-cyclopropyl]-carbamic acid benzyl ester (1.33g, 4.55mmol, 45%).
[M+H]+ = 293.04 1H NMR: (CDCI3), δ: 1.24 (6H, t, J = 7.2 Hz), 3.02 (4H, q, J = 7.2 Hz), 4.70 (2H, s), 7.34 - 7.37 (5H, m), 7.77 (2H, d, J = 8.4 Hz), 8.04 (2H, d, J = 8.6 Hz). C. {1-[4-(tert-Butoxycarbonylamino-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester [1-(4-Cyano-phenyl)-cyclopropyl]-carbamic acid benzyl ester (1.33g, 4.55mmol) was dissolved in methanol (100mls). This solution was cooled to 0°C. Nickel (II) chloride hexahydrate (108mg, 0.46mmol) and di-tertbutyl dicarbonate (1.99g, 9.10mmol) were added followed by sodium borohydride (1.21 g, 31.85mmol) portionwise. The reaction mixture was stirred at 0°C to room temp for 18 hours. The MeOH was removed by evaporation. The residue was dissolved in CHCI3 (70mls), washed with sat NaHCO3(1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a yellow oil. Purified by flash chromatography, (silica), eluant 30%Pet. Ether (60-80°C), 70% EtOActo give white solid identified as {1-[4-(tert-butoxycarbonylamino-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester (1.06g, 2.67mmol, 59%).
[M+H]+ = 419.2 (M+Na). D. [1-(4-Aminomethyl-phenyl)-cyclopropyl]-carbamic acid benzyl ester Hydrochloride {1-[4-(tert-butoxycarbonylamino-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester (90mg, 0.23mmol) was dissolved in 4M HCI in dioxan (10mls). After 3 hours at room temperature the solvent was removed in vacuo to give a yellow solid identified as [1-(4-aminomethyl-phenyl)-cyclopropyl]-carbamic acid benzyl ester hydrochloride (84mg, 0.23mmol, 100%).
[M+H]+ = 318.97 (M+Na). E. {1 -[4-({[2,5-Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (78mg, 0.25mmol) was dissolved in CH2CI2(20mls). This solution was cooled to 0°C. [1-(4-Aminomethyl-phenyl)-cyclopropyl]-carbamic acid benzyl ester hydrochloride (84mg, 0.23mmol) was added followed by HOBt (37mg, 0.27mmol) and triethylamine (115mg, 1.14mmol). Water soluble carbodiimide (61 mg, 0.32mmol) was then added. After 18 hrs at 0°C to room temperature reaction mixture was diluted with chloroform (100mls) and washed with NaHC03 (1x20mls), water (1x20mls), brine (1x20mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 50%Pet. Ether (60-80°C), 50% EtOAc, fractions combined and evaporated in vacuo to give a white solid identified as {1-[4-({[2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carbonyl]-amino}-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester (66mg, 0.11mmol, 49%). F. 2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-(1-amino-cyclopropyl)-benzylamide {1-[4-({[2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carbonyl]-amino}-methyl)-phenyl]-cyclopropyl}-carbamic acid benzyl ester (70mg, 0.12mmol) was dissolved in methanol (40mls). This solution was hydrogenated over 10% Pd/C (10mg) at atmospheric pressure and room temperature for 5 hours after which time the catalyst was filtered off and washed with methanol (30mls), the combined filtrates were evaporated in vacuo and freeze dried from acetonitrile and water to give a white solid identified as 2,5-dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-(1-amino-cyclopropyl)-benzylamide (21mg, 0.046mmol, 38%).
[M+H]+ = 480.16. 1H NMR: (d6-DMSO) δ: 0.75 (2H, t, J = 7.4 Hz), 1.45-1.57 (2H, m), 2.25 (3H, s), 2.55 (3H, s), 3.63 (1H, t, J = 6.7 Hz), 4.32 (2H, d, J = 6.1 Hz), 5.16 (2H, s), 6.29 (2H, s), 7.18 (2H, d, J = 8.0 Hz), 7.23 (2H, d, J = 8.0 Hz), 7.25 (1H, s), 7.49 (2H, d, J = 1.8 Hz), 7.50-7.51 (1H, m), 7.89 (1H, d, J = 1.7 Hz), 7.91 (1H, d, J = 2.6 Hz), 8.03 (1H, t, J = 6.1 Hz). REFERENCE EXAMPLE 5 1 -r4-(2-Oxo-2H-pyridin-1 -ylmethyD-benzyll-l H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide
A. 1-(4-Chloromethyl-benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester
Polymer-supported triphenylphospine (3.0mmol/g, 3 equiv, 1.0g) was swollen in THF/dichloromethane (1:1, 100mls) under a nitrogen atmosphere. Ethyl 1 H-pyrazole-4-carboxylate (500mg, 3.57mmol) and 4-(chloromethyl)benzyl alcohol (671 mg, 4.28mmol) were added followed by a solution of diisopropyl azodicarboxylate (1.08g, 5.35mmol) in THF/dichloromethane (1:1, 10mls) over a period of 30mins. The reaction mixture was stirred at room temperature for 18 hours, the mixture was filtered through celite and the resin was washed with 3 cycles of dichloromethane/methanol (15mls). The combined filtrates were evaporated in vacuo and triturated with ethanol to give a white solid identified as 1-(4-chloromethyl-benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester (741 mg, 2.66mmol, 75%).
[M+H]+ = 279.05 B. 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester 1-(4-Chloromethyl-benzyl)-1H-pyrazole-4-carboxylic acid ethyl ester (300mg, 1.076mmol) was dissolved in acetone (50mls) 2-hydroxypyridine (123mg, 0.001 mmol) and potassium carbonate (446mg, 0.003mmol) were added and the reaction mixture was stirred at 50°C for 3 hours after which time the solvent was removed in vacuo and the residue taken up in EtOAc (100mls), this solution was washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a colourless oil identified as 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester (310mg, 0.92, 85%).
[M+H]+ = 337.78, 350.84 (M+Na). C. 1 -[4-(2-Oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl este (310mg, 0.92mmol) was dissolved in THF (50mls)and water (5mls) lithium hydroxide (110mg, 4.6mmol) was added. The reaction mixture was stirred at 50°C for 18 hours after which time the solvent was concentrated in vacuo and the residue taken up in EtOAc (50mls), the aqueous layer was separated, acidified with 1M HCI to pH2 and extracted CHCI3(3x50mls) the combined extracts were washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a colourless oil identified as 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (140mg, 0.453mmol, 49%).
[M+H]+ = 309.93 D. {4-[({1 -[4-(2-Oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid (130mg, 0.42mmol) was dissolved in CH2CI2(50mls) and DMF (2.5mls). This solution was cooled to 0°C. tert-Butyl 4-(Aminomethyl)benzylcarbamate (119mg, 0.50mmol) was added followed by HOBt (62mg, 0.46mmol) and triethylamine (128mg, 1.27mmol). Water soluble carbodiimide (97mg, 0.50mmol) was then added. After 18 hours at 0°C to room temperature reaction mixture was diluted with chloroform (400mls) washed with 0.3M KHS04 (1x30mls), NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 6%MeOH, 94% CHCI3, fractions combined and evaporated in vacuo to give a white solid identified as {4-[({1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester (156mg, 0.296mmol, 70%).
[M+H]+ = 550.45 E. 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide Hydrochloride {4-[({1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester (52mg, O.IOmmol) was dissolved in 4M HCI in dioxan (25mls). After one hour at room temperature the solvent was removed in vacuo. The residue was slurried with acetone and the solid was filtered off to give a white solid identified as 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide hydrochloride (89mg, 0.19mmol, 47%).
[M+H]+ = 428.32 1H NMR: (d6-DMSO), δ: 3.97 (2H, q, J = 5.72Hz), 4.38 (2H, dq, J = 6.06Hz), 5.08 (2H, s), 5.31 (2H, s), 6.23 (1H, q, J = 6.34Hz), 6.40 (1H, d, J = 5.72Hz), 7.22- 7.32 (6H, m), 7.41-7.44 (2H, m), 7.77 (1H, d, J = 6.62Hz), 7.91 (1H, s), 8.27 (1H, s), 8.39 (3H, s, br), 8.71-8.74 (1H, m). REFERENCE EXAMPLE 6 1 -r4-(2-Oxo-2H-pyridin-1 -ylmethyD-benzyll-l H-Π .2,31triazole-4-carboxvlic acid 4-aminomethyl-benzylamide
A. 1 -(4-Hydroxymethyl-benzyl)-1 H-pyridin-2-one 4-(Chloromethyl)benzylalcohol (1.0g, 6.38mmol) was dissolved in acetone (50mls) 2-hydroxypyridine (729mg, 7.66mmol) and potassium carbonate (2.65g, 19.20mmol) were added and the reaction mixture was stirred at 50°C for 3 hours after which time the solvent was removed in vacuo and the residue taken up in chloroform (100mls), this solution was washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a white solid identified as 1-(4-hydroxymethyl-benzyl)-1H-pyridin-2-one (1.1 Og, 5.11, 80%) [M+H]+ = 238.09 (M+Na) B. 1 -(4-Azidomethyl-benzyl)-1 H-pyridin-2-one 1-(4-Hydroxymethyl-benzyl)-1H-pyridin-2-one (570mg, 2.65mmol) and DBU (806mg, 5.30mmol) were dissolved in DMF (20mls). Diphenylphosphoryl azide (1.09g, 3.97mmol) was added and the reaction mixture was stirred at room temperature for 3 hours after which time the reaction mixture was diluted with EtOAc (100mls), this solution was washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a white foamy solid identified as 1-(4-azidomethyl-benzyl)-1H-pyridin-2-one (430mg, 1.79mmol, 68%).
[M+H]+ = 360.90 (M+Na). C. 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester 1-(4-Azidomethyl-benzyl)-1H-pyridin-2-one (340mg, 1.41 mmol), ethyl propiolate (139mg, 1.41 mmol), (+)-sodium L-ascorbate (280mg, 1.41 mmol) and copper (II) sulphate pentahydrate (71 mg, 0.28mmol) were dissolved in tert-butanol (20mls) and water (5mls). The reaction mixture was stirred at room temperature for 18 hours after which time the reaction mixture was diluted with chloroform (100mls), this solution was washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was triturated with ethyl acetate and pet ether 60-80 to give a white solid identified as 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester (11 Omg, 0.33mmol, 23%). [M+H]+ = 486.18 D. 1 -[4-(2-Oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-[1,2,3]triazole-4-carboxylic acid 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester (110mg, 0.32mmol) was dissolved in THF(50mls) and water (5mls), lithium hydroxide (39mg, 1.62mmol) was added. The reaction mixture was stirred at 50°C for 18 hours after which time the solvent was concentrated in vacuo and the residue taken up in EtOAc (50mls), the aqueous layer was separated, acidified with 1M HCI to pH2 and extracted CHCI3(3x50mls) the combined extracts were washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a colourless oil identified as 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid (80mg, 0.26mmol, 79%). E. {4-[({1 -[4-(2-Oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-[1,2,3]triazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid (80mg, 0.26mmol) was dissolved in CH2CI2(50mls) and DMF(2.5mls). This solution was cooled to 0°C. tert-Butyl 4-(aminomethyl)benzylcarbamate (73mg, 0.31 mmol) was added followed by HOBt (38mg, 0.28mmol) and triethylamine (78mg, 0.77mmol). Water soluble carbodiimide (59mg, 0.31 mmol) was then added. After 18 hours at 0°C to room temperature reaction mixture was diluted with chloroform (400mls) washed with 0.3M KHS04 (1x30mls), NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo giving a yellow oil. The residue was purified by flash chromatography (silica), eluant 6%MeOH, 94% CHCI3, fractions combined and evaporated in vacuo to give a white solid identified as {4-[({1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester (85mg, 0.166mmol, 62%).
[M+H]+ = 550.45 F. 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide Hydrochloride {4-[({1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carbonyl}-amino)-methyl]-benzyl}-carbamic acid tert-butyl ester (85mg, 0.16mmol) was dissolved in 4M HCI in dioxan (25mls). After one hour at room temperature the solvent was removed in vacuo. The residue was slurried with acetone and the solid was filtered off to give a white solid identified 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide hydrochloride (76mg, 0.18mmol, 60%).
[M+H]+ = 429.10 1H NMR: (d6-DMSO), δ: 4.00 (2H, q, J = 5.72Hz), 4.43 (2H, q, J = 6.25Hz), 5.08 (2H, s), 5.31 (2H, s), 6.23 (1H, q, J = 6.52Hz), 6.40 (1H, d, J = 8.92Hz), 7.27- 7.48 (7H, m), 7.77 (1H, q, J = 8.82Hz), 7.91 (1H, s), 8.21 (3H, s, br), 8.64 (1H, s), 9.12 (1H, t, J = 5.83Hz). REFERENCE EXAMPLE 7 1 -(2-Methyl-quinolin-6-vlmethyl)-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide
A. (4-{[(1H-Pyrazole-4-carbonyl)-amino]-methyl}-benzyl)-carbamic acid tert-butyl ester 4-Pyrazolecarboxylic acid (400mg, 3.57mmol) was dissolved in CH2CI2(50mls) and DMF(2.5mls). This solution was cooled to 0°C. tert-Butyl 4-(aminomethyl)benzylcarbamate (1.01 g, 4.28mmol) was added followed by HOBt (530mg, 3.93mmol) and triethylamine (1.08g, 10.71 mmol). Water soluble carbodiimide (821 mg, 4.28mmol) was then added. After 18 hours at 0°C to room temperature reaction mixture was diluted with chloroform (400mls) washed with 0.3M KHS04 (1x30mls), NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo giving a yellow oil. The residue was purified by flash chromatography (silica), eluant 7%MeOH, 93% CHCI3, fractions combined and evaporated in vacuo to give a white solid identified as (4-{[(1 H-pyrazole-4-carbonyl)-amino]-methyl}-benzyl)-carbamic acid tert-butyl ester (1.1 Og, 3.33mmol, 93%).
[M+H]+ = 352.95 (M+Na) B. (2-Methyl-quinolin-6-yl)-methanol 2-Methyl-quinoline-6-carboxylic acid (1 .Og, 5.34mmol) was dissolved in THF (100mls), this solution was cooled to -20°C, to this solution was added triethylamine (1.62g, 16.03mmol) and isobutyl chloroformate (875mg, 6.41 mmol). The reaction mixture was stirred at -20°C for 20mins and then poured into a solution of sodium borohydride (1 .Og, 26.71 mmol) in water (10mls) at 0°C. The reaction mixture was stirred at 0°C to room temperature for 18 hours and diluted with EtOAc (200mls) 0.3M KHS04 (1x50mls), water (1x50mls), brine (1x50mls), dried (Na2S04) and evaporated in vacuo to give a white solid. The solid were triturated with EtOAc/Pet Ether 60-80°Cto give a white solid identified as (2-methyl-quinolin-6-yl)-methanol (890mg, 5.14mmol, 96%).
[M+H]+ = 174.24 C. 6-Bromomethyl-2-methyl-quinoline (2-Methyl-quinolin-6-yl)-methanol (150mg, 0.87mmol) was dissolved in dichloromethane (50mls). To this solution was added phosphorous tribromide (215mg, 2.13mmol) The reaction mixture was stirred at room temperature for 18 hours and diluted with CHCI3 (100mls) the filtrate was washed with sat. NaHC03 (1x30mls), water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo to give a white solid which was identified as 6-bromomethyl-2-methyl-quinoline (180mg, 0.76mmol, 88%).
[M+H]+ = 235.96 D. [4-({[1 -(2-Methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 6-Bromomethyl-2-methyl-quinoline (180mg, 0.76mmol) was dissolved in DMF (10mls). (4-{[(1H-Pyrazole-4-carbonyl)-amino]-methyl}-benzyl)-carbamic acid tert-butyl ester (302mg, 0.915mmol) and cesium carbonate (745mg, 2.29mmol) were added and the reaction mixture was stirred at 50°C for 18 hours after which time the reaction mixture was diluted with EtOAc (100mls), this solution was washed with water (1x30mls), brine (1x30mls), dried (Na2S04) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluant 3%MeOH, 97% CHCI3, fractions combined and evaporated in vacuo to give a white foamy solid identified as [4-({[1 -(2-methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester (145mg, 0.30mmol, 39%).
[M+H]+ = 486.18 E. 1-(2-Methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide Hydrochloride [4-({[1-(2-Methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester (145mg, 0.30mmol) was dissolved in 4M HCI in dioxan (25mls). After one hour at room temperature the solvent was removed in vacuo. The residue was slurried with acetone and the solid was filtered off to give a white solid identified as 1-(2-methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide hydrochloride (76mg, 0.18mmol, 60%).
[M+H]+ = 385.94 1H NMR: (d6-DMSO), δ: 2.97 (3H, s), 3.98 (2H, q, J = 5.53Hz), 4.40 (2H, d, J = 6.00Hz), 5.66 (2H, s), 7.32 (2H, d, J = 8.02Hz), 7.42 (2H, d, J = 8.30Hz), 7.94-7.99 (1H, m), 8.00 (1H, s), 8.10 (1H, s), 8.37-8.43 (5H, m), 8.82 (1H, t, J = 6.09Hz), 9.00 (1H, d, J = 8.60Hz).
The compounds in the following tables were synthesised as described for Examples 1 to 4 and reference examples 5-7.
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11
Table 12
Table 13
Table 14 NMR data of examples
Biological Methods
The ability of the compounds of formula (I) to inhibit plasma kallikrein may be determined using the following biological assays:
Determination of the ICfin for plasma kallikrein
Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen etai, Int. J. Tiss. Reac. 1986, 8, 185; Shori etai, Biochem. Pharmacol., 1992, 43, 1209; Sturzebecheretai., Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human plasma kallikrein (Protogen) was incubated at 37°C with the fluorogenic substrate H-DPro-Phe-Arg-AFC and various concentrations of the test compound. Residual enzyme activity (initial rate of reaction) was determined by measuring the change in optical absorbance at 410nm and the IC50 value for the test compound was determined.
Data acquired from these assays are shown in Table 15 below. Generally, but not exclusively, preferred compounds demonstrate an IC50 of less than 200 nM.
Table 15
Selected compounds were further screened for inhibitory activity against the related enzyme KLK1. The ability of the compounds of formula (I) to inhibit KLK1 may be determined using the following biological assay:
Determination of the IC50 for KLK1 KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen etai, Int. J. Tiss. Reac. 1986, 8, 185; Shori etai, Biochem. Pharmacol., 1992, 43, 1209; Sturzebecheref a/., Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human KLK1 (Callbiochem) was incubated at 37°C with the fluorogenic substrate H-DVal-Leu-Arg-AFC and various concentrations of the test compound. Residual enzyme activity (initial rate of reaction) was determined by measuring the change in optical absorbance at 410nm and the IC50 value for the test compound was determined.
Data acquired from this assay are shown in Table 16 below:
Table 16 (KLK1 Activity)
Selected compounds were further screened for inhibitory activity against the related enzymes plasmin, thrombin, trypsin, Factor Xa and Factor Xlla. The ability of the compounds of formula (I) to these enzymes may be determined using the following biological assays:
Determination of enzyme selectivity
Human serine protease enzymes plasmin, thrombin, trypsin, Factor Xa and Factor Xlla were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease activity was measured by monitoring the accumulation of liberated fluorescence from the substrate over 5 minutes. The linear rate of fluorescence increase per minute was expressed as percentage (%) activity. The Km for the cleavage of each substrate was determined by standard transformation of the Michaelis-Menten equation. The compound inhibitor assays were performed at substrate Km concentration and activities were calculated as the concentration of inhibitor giving 50% inhibition (IC50) of the uninhibited enzyme activity (100%).
Data acquired from these assays are shown in Table 17 below:
Table 17 (Selectivity data)
Pharmacokinetics
Pharmacokinetic studies of selected examples were performed to assess the pharmacokinetics following a single oral dose in male Sprague-Dawley rats. Typically, either two or three rats were given a single po dose of 5 ml_/kg of a nominal 2 mg/mL (10 mg/kg) composition of test compound in either 5% cremophor:5% ethanol:90% phosphate buffered saline or 20% Labrasol:80% water. Following dosing, blood samples were collected over a period of 8 hours. Typical sample times include 5, 15 and 30 minutes then 1, 2, 4, 6 and 8 hours. Following collection, blood samples were centrifuged and the plasma fraction analysed for concentration of test compound by LCMS. Oral exposure data acquired from these studies are shown below:
Table 18 (Oral exposure data)
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (23)

  1. THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
    1. A compound of formula (I),
    Formula (I) wherein, V is selected from C and N such that the aromatic ring containing V is phenyl or pyridine; R2 is absent when V is N; or, when present, R2 is selected from H, alkyl, alkoxy, CN, halo and CF3; R1 and R3 are independently selected from H, alkyl, alkoxy, CN, halo and CF3; W, X, Y and Z are independently selected from C, N, O and S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; wherein, R5, R6 and R7 are independently absent or independently selected from H, alkyl, halo, aryl, heteroaryl and CF3; P is -C(R10)(R11)NH2; R8 and R9 are independently selected from H and alkyl, or may together form a cycloalkyl ring; R10 and R11 are independently selected from H and alkyl, or may together form a cycloalkyl ring or a cyclic ether; A is selected from N-linked morpholine, aryl, and heteroaryl; alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (CrC^) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (Cr C6)alkoxy, OH, CN, CF3, -COOR12, -CONR12R13, H(CH2)1_3CON(R12)( CH,)^-, fluoro and -NR12R13; cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms; wherein cycloalkyl may be optionally substituted with a substituent selected from alkyl, alkoxy and NR12R13; a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom; alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (CrC6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from aryl, OH, CN, CF3, -COOR12, -CONR12R13, fluoro and NR12R13; aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i-3-arylb, -(CH^.s-heteroaryl, -COOR12, -CONR12R13, -(CH2)i_3-NR14R15, CF3 and NR12R13; arylb is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13 heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O; heteroaryl may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i-3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and NR12R13; heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O; wherein heteroarylb may be optionally substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)i-3-aryl, -COOR12, -CONR12R13, CF3 and NR12R13; R12 and R13 are independently selected from H and alkyl; or R12 and R13 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted; wherein, when R5, R6 and R7 are absent or H, then: either R10 and R11 together form a cycloalkyl ring or a cyclic ether; or A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1,2 or 3 substituents independently selected from OH, heteroaryl, arylb, -0-arylb, -(CH2)r3-arylb, -(CH^-s-heteroaryl, -COOR12, -CONR12R13, and -(CH2)3-NR14R15; wherein, arylb is phenyl, biphenyl or naphthyl, wherein arylb is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF3 and NR12R13; and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, -(CH2)1.3-aryl, heteroarylb, -COOR12, -CONR12R13, CF3 and -NR12R13; or A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1,2 or 3 substituents independently selected from aryl, -(CH2)i-3-aryl, heteroarylb, -C00R12, and -CONR12R13;wherein, aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, arylb, -0-arylb, -(CH2)i-3-arylb, -(CH2)1.3-heteroaryl, -C00R12, -CONR12R13, -COR12R13, -(CH2)1_3-NR14R15, CF3 and -NR12R13; and heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1,2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroarylb is substituted with 1,2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, -(CH2)1.3-aryl, -C00R12, -CONR12R13, CF3 and NR12R13; or a tautomer, stereoisomer (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salt or solvate thereof.
  2. 2. A compound according to claim 1 wherein at least one of R5, R6 and R7 is selected from alkyl, halo, aryl, heteroaryl and CF3.
  3. 3. A compound according to claim 1 or claim 2 wherein A is selected from:
  4. 4. A compound according to any one of claims 1 to 3 wherein A is:
  5. 5. A compound according to claim 1 wherein R5, R6 and R7 are absent or H; and A is selected from:
  6. 6. A compound according to any one of claims 1 to 4 wherein, X is N and W, Y and Z are C.
  7. 7. A compound according to claim 6 wherein, R5 is H, and R6 and R7 are methyl.
  8. 8. A compound according to any one of claims 1 to 5 wherein, X and Y are N and W and Z are C.
  9. 9. A compound according to any one of claims 1 to 5 wherein, X, Y and Z are N and WisC.
  10. 10. A compound according to any one of claims 1 to 9 wherein R8 and R9 are H.
  11. 11. A compound according to any one of claims 1 to 5, wherein: WisC; X is N; YisC; Z is C; R5 is H; R6 and R7 are CH3; R8 and R9 are H; and R10 and R11 are both H or together form a cyclopropane ring.
  12. 12. A compound according to any one of claims 1 to 11 wherein V is C.
  13. 13. A compound according to any one of claims 1 to 12 wherein R1 is selected from alkyl, alkoxy, CN, halo and CF3.
  14. 14. A compound according to any one of claims 1 to 13 wherein R1 is alkyl.
  15. 15. A compound according to any one of claims 1 to 14 wherein R3 is alkyl.
  16. 16. A compound according to claim 1 selected from: 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-(l-amino-cyclopropyl)-benzylamide; 2.5- Dimethyl-1-(6-phenyl-pyridin-2-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 1-[2-(3-Fluoro-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1-(2-thiophen-3-yl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid (6-aminomethyl-pyridin-3-ylmethyl)-amide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-fluoro-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-chloro-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-trifluoromethyl-benzylamide; 2.5- Dimethyl-1 -(2-phenyl-thiazol-4-ylmethyl)-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methoxy-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1 -[4-(3,5-Dimethyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1 -[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1 -[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1 -[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 2.5- Dimethyl-1 -[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide; 2.5- Dimethyl-1 -[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 2.5- Dimethyl-1 -[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-imidazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1 H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
    1 -Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1 -ylmethyl)-benzyl]-1 H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
    5-Methyl-1 -[4-(4-methyl-pyrazol-1 -ylmethyl)-benzyl]-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1 -[4-(4-Methyl-pyrazol-1 -ylmethyl)-benzyl]-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide; 1 -[4-(4-Methyl-pyrazol-1 -ylmethyl)-benzyl]-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1 -[4-(4-Methyl-pyrazol-1 -ylmethyl)-benzyl]-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-2-methyl-benzylamide; 3-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
    5-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1-(2-Methyl-quinolin-6-ylmethyl)-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; 1 -(2-Pyrrolidin-1 -yl-pyridin-4-ylmethyl)-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide; and pharmaceutically acceptable salts and solvates thereof.
  17. 17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier, diluent or excipient.
  18. 18. The use of a compound according to any one of claims 1 to 16 in the manufacture of a medicament for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
  19. 19. A method of treatment of a disease or condition in which plasma kallikrein activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 16.
  20. 20. The use of claim 18, or the method of claim 19 wherein, the disease or condition in which plasma kallikrein activity is implicated is selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery and bleeding from post operative surgery.
  21. 21. The use of claim 18, or the method of claim 19, wherein the disease or condition in which plasma kallikrein activity is implicated is retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
  22. 22. The use of claim 18, or the method of claim 19, wherein the disease or condition in which plasma kallikrein activity is implicated is diabetic macular edema.
  23. 23. The use of claim 18, or the method of claim 19, wherein the disease or condition in which plasma kallikrein activity is implicated is hereditary angioedema.
AU2014204666A 2013-01-08 2014-01-08 Benzylamine derivatives Ceased AU2014204666B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361750074P 2013-01-08 2013-01-08
US61/750,074 2013-01-08
GBGB1300304.1A GB201300304D0 (en) 2013-01-08 2013-01-08 Benzylamine derivatives
GB1300304.1 2013-01-08
US201361865732P 2013-08-14 2013-08-14
US61/865,732 2013-08-14
PCT/GB2014/050043 WO2014108679A1 (en) 2013-01-08 2014-01-08 Benzylamine derivatives

Publications (2)

Publication Number Publication Date
AU2014204666A1 AU2014204666A1 (en) 2015-07-23
AU2014204666B2 true AU2014204666B2 (en) 2017-09-14

Family

ID=47748123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014204666A Ceased AU2014204666B2 (en) 2013-01-08 2014-01-08 Benzylamine derivatives

Country Status (18)

Country Link
US (1) US9670157B2 (en)
EP (1) EP2943483B1 (en)
JP (1) JP6430398B2 (en)
KR (1) KR102185928B1 (en)
CN (1) CN105143201B (en)
AU (1) AU2014204666B2 (en)
BR (1) BR112015016293B1 (en)
CA (1) CA2897273C (en)
ES (1) ES2623895T3 (en)
GB (1) GB201300304D0 (en)
HU (1) HUE033243T2 (en)
MX (1) MX362889B (en)
MY (1) MY182590A (en)
NZ (1) NZ709609A (en)
PL (1) PL2943483T3 (en)
RU (1) RU2660421C2 (en)
SG (1) SG11201505309TA (en)
WO (1) WO2014108679A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101937514B1 (en) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906551B1 (en) 2012-10-12 2018-02-28 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6479763B2 (en) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors
MX366498B (en) * 2013-08-14 2019-07-11 Kalvista Pharmaceuticals Ltd Inhibitors of plasma kallikrein.
TWI636047B (en) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 Heterocyclic derivatives
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
US20170002006A1 (en) 2014-01-31 2017-01-05 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
ES2714283T3 (en) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrocycles of diamide that are inhibitors of FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
SG10202003705WA (en) 2015-10-01 2020-06-29 Biocryst Pharm Inc Human plasma kallikrein inhibitors
EP3464271B1 (en) * 2016-05-31 2020-05-13 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
US11168080B2 (en) 2017-04-26 2021-11-09 Mitobridge, Inc. Dynamin-1-like protein inhibitors
SI3716952T1 (en) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4017850A1 (en) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
EP4017849A1 (en) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
RU2734970C1 (en) * 2019-12-10 2020-10-26 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" System for delivery of 2-ethyl-6-methyl-3-hydroxypyridine succinate for oral administration in form of gastroretentive tablet
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer
WO2022079446A1 (en) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022084693A1 (en) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (en) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド Treatment of hereditary angioedema
CN115073429A (en) * 2021-03-15 2022-09-20 昆药集团股份有限公司 Salt form and crystal form of 1,2, 4-triazine-3, 5-diketone compound and preparation method thereof
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023185634A1 (en) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 Heterocyclic compound as plasma kallikrein inhibitor
DK4288036T3 (en) 2022-04-27 2024-08-26 Kalvista Pharmaceuticals Ltd Formulations of a plasma kallikrein inhibitor
WO2024180100A1 (en) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
AU759310B2 (en) * 1998-08-20 2003-04-10 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
US7101878B1 (en) * 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
DE10301300B4 (en) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
US7247654B2 (en) * 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
CA2903196A1 (en) 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
EP1981854B1 (en) * 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2007070818A1 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) * 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
EP2259679A4 (en) 2008-01-31 2011-09-14 Joslin Diabetes Ct Methods for treatment of kallikrein-related disorders
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
JP5537442B2 (en) * 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Pyridazine derivatives as factor XIA inhibitors
JP2013515000A (en) * 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド Prodrugs for inhibitors of plasma kallikrein
CA2788417C (en) 2010-01-28 2017-02-14 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, and their preparation and use
JP2013121919A (en) 2010-03-25 2013-06-20 Astellas Pharma Inc Plasma kallikrein inhibitor
ES2483802T3 (en) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
ES2636312T3 (en) * 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as inhibitors of HIV fixation
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) * 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2014108406A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein

Also Published As

Publication number Publication date
ES2623895T3 (en) 2017-07-12
CA2897273C (en) 2021-05-18
JP2016504378A (en) 2016-02-12
RU2015133171A (en) 2017-02-15
CN105143201B (en) 2019-02-22
MX2015008835A (en) 2016-02-05
AU2014204666A1 (en) 2015-07-23
KR20150115791A (en) 2015-10-14
PL2943483T3 (en) 2017-08-31
US20160039752A1 (en) 2016-02-11
EP2943483B1 (en) 2017-03-01
RU2660421C2 (en) 2018-07-06
MY182590A (en) 2021-01-26
US9670157B2 (en) 2017-06-06
BR112015016293B1 (en) 2022-10-18
KR102185928B1 (en) 2020-12-02
WO2014108679A1 (en) 2014-07-17
EP2943483A1 (en) 2015-11-18
CA2897273A1 (en) 2014-07-17
HUE033243T2 (en) 2017-11-28
MX362889B (en) 2019-02-22
BR112015016293A2 (en) 2017-07-11
SG11201505309TA (en) 2015-08-28
GB201300304D0 (en) 2013-02-20
NZ709609A (en) 2020-07-31
CN105143201A (en) 2015-12-09
JP6430398B2 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
AU2014204666B2 (en) Benzylamine derivatives
US11084809B2 (en) N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
AU2021200140B2 (en) Pyrazole derivatives as plasma kallikrein inhibitors
US9533987B2 (en) Heterocyclic derivates
US10781181B2 (en) N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US9834513B2 (en) Benzylamine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired